Phosphorylated S6 Kinase-1 as Predictive Marker of Lapatinib Efficacy in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
Journal of Breast Disease
;
(2): 57-63, 2017.
Artículo
en Inglés
| WPRIM
| ID: wpr-652800
ABSTRACT
PURPOSE:
The 40S ribosomal protein S6 kinase-1 (S6K1) is a crucial downstream effector of the PI3K/AKT/mTOR pathway. S6K1 overexpression is found in 10% to 30% of breast cancers and is associated with aggressive disease and poor prognosis. Herein, we investigated the relationship between the expression of phosphorylated S6K1 (p-S6K1) and efficacy of lapatinib in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.METHODS:
We retrospectively analyzed the data of 36 patients with HER2-positive metastatic breast cancer treated with lapatinib between January 2010 and September 2014. The p-S6K1 expression status of the primary tumor was assessed via immunohistochemistry using a mouse monoclonal antibody.RESULTS:
Fourteen of the 36 patients (38.9%) had p-S6K1-positive tumors. The median progression-free survival (PFS) of patients with p-S6K1-positive tumors was significantly longer than that of patients with p-S6K1-negative tumors (13.4 months vs. 7.1 months, p=0.025). In multivariate analysis, p-S6K1 positivity remained an independent, favorable predictive factor for PFS (hazard ratio, 0.32; 95% confidence interval, 0.11–0.97; p=0.044).CONCLUSION:
The high expression of p-S6K1 was significantly associated with prolonged PFS, suggesting that p-S6K1 can be a potential biomarker for predicting the efficacy of lapatinib in patients with HER2-positive metastatic breast cancer.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pronóstico
/
Mama
/
Neoplasias de la Mama
/
Inmunohistoquímica
/
Análisis Multivariante
/
Estudios Retrospectivos
/
Supervivencia sin Enfermedad
/
Proteínas Quinasas S6 Ribosómicas
/
Proteína S6 Ribosómica
/
Factor de Crecimiento Epidérmico
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Animales
/
Humanos
Idioma:
Inglés
Revista:
Journal of Breast Disease
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS